Hepatitis gene therapy leads Bay Area trio of year-end FDA approval requests
Approaching the end of long drug-development journeys, these three Bay Area companies formally asked the FDA to approve potential treatments for hemophilia A, anemia in chronic kidney disease patients and migraines.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Anemia | Biotechnology | Chronic Kidney Disease | Gene Therapy | Genetics | Haemophilia | Headache | Health Management | Hemophilia | Hepatitis | Migraine | Urology & Nephrology